US Executive Compensation Proxy SEC Filings — October 01, 2026

01-10-2026

HCW Biologics Inc. filed a DEF 14A proxy statement on October 1, 2026, seeking stockholder approval for the issuance of up to 618,682 shares of common stock upon exercise of Common Warrants issued in a July 29, 2026 private placement with Armistice Capital Master Fund Ltd. and certain inside investors. Approval is required under Nasdaq Listing Rule 5635(d) because the potential issuance exceeds 19.99% of outstanding shares. If approved, existing stockholders will face dilution; if not approved, the company may not receive additional capital from warrant exercises, limiting the financing benefits of the offering.

• · The Common Warrants have a term of 5.5 years from the Initial Exercise Date (July 29, 2026).
• · The offering closed on July 29, 2026, but Common Warrants are issuable only upon stockholder approval.
• · If Proposal One is not approved, the Common Warrants remain outstanding but cannot be exercised beyond the Exchange Cap (319,370 shares).
• · The Board recommends a vote FOR Proposal One.
• · The company expects to retain Advantage Proxy to solicit votes on behalf of the board.
• · Abstentions and broker non-votes will have no effect on the outcome if determined to be a 'votes cast' matter.

01-10-2026

Research Solutions, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled as a virtual meeting on November 16, 2026. Stockholders will vote on the election of six directors, ratification of Wipfli LLP as independent auditor for FY ending June 30, 2027, and a non-binding advisory vote on executive compensation. The record date is September 17, 2026, with 33,762,669 shares outstanding and entitled to vote.

• · Annual Meeting will be held virtually on November 16, 2026 at 11:00 a.m. Pacific Time.
• · Record date for voting is September 17, 2026.
• · 33,762,669 shares of common stock outstanding and entitled to vote as of record date.
• · Proxy materials first made available on or about September 30, 2026.
• · Board recommends voting FOR all proposals: election of six directors, ratification of Wipfli LLP, and advisory vote on executive compensation.

01-10-2026

Lightstone Value Plus REIT III, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on December 14, 2026. The meeting will involve the election of three directors to the Board. The company has 12.4 million shares outstanding as of the record date of September 30, 2026, and the Board recommends voting FOR all nominees.

• · The meeting will be held at 299 Park Avenue, New York, NY on December 14, 2026 at 10:45 a.m. EST.
• · The Sponsor (The Lightstone Group LLC) owned 222,222 shares and the Advisor owned 20,000 shares as of the record date; both will abstain from voting on director elections.
• · A quorum requires a majority of votes entitled to be cast; broker non-votes and withheld votes count against director nominees.
• · The proxy statement was first mailed to stockholders on or about October 7, 2026.
• · Stockholders can vote via Internet, telephone, or mail, with a toll-free number provided (800-337-3503).

01-10-2026

Lightstone Value Plus REIT IV, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on December 14, 2026. The meeting will include the election of three directors to serve until the 2027 annual meeting. The record date for voting is September 30, 2026, with 7.8 million shares outstanding, though The Lightstone Group LLC (Sponsor) and Lightstone Real Estate Income LLC (Advisor) will abstain from voting their shares in the director election.

• · The annual meeting will be held at 299 Park Avenue, New York, NY 10171 at 11:15 a.m. EST on December 14, 2026.
• · The record date for voting is September 30, 2026.
• · The Sponsor and Advisor, affiliated with director David Lichtenstein, will abstain from voting their shares in the director election.
• · Stockholders can vote via Internet, telephone, or mail; proxy materials first mailed on or about October 7, 2026.
• · The 2025 Annual Report on Form 10-K was previously mailed on or about April 15, 2026.

01-10-2026

Lightstone Value Plus REIT II, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on December 14, 2026. The sole proposal is the election of three directors to serve until the 2027 Annual Meeting. The Board of Directors recommends voting FOR all nominees. The record date for voting is September 30, 2026, and the company has engaged Computershare Fund Services for proxy solicitation at a fee of $20,000.

• · Proxy materials first mailed to stockholders on or about October 7, 2026.
• · 2025 Annual Report on Form 10-K was previously mailed on April 15, 2026.
• · A quorum requires presence of stockholders entitled to cast a majority of all votes entitled to be cast.
• · Each director nominee must receive a majority of votes present in person or by proxy; withheld votes and broker non-votes count against.
• · The Advisor will abstain from voting its 20,000 shares in the election of directors.
• · Stockholders can vote via Internet, telephone, or mail; in-person voting also available at the meeting.

01-10-2026

Lightstone Value Plus REIT I, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on December 14, 2026. The primary agenda is the election of four directors. The filing details voting procedures, quorum requirements, and notes that the external advisor (Lightstone Value Plus REIT LLC) and its affiliates, holding 20,000 shares, will abstain from voting in the director election. The company has 20.7 million shares outstanding as of the record date of September 30, 2026.

• · The annual meeting will be held at 299 Park Avenue, New York, New York, 10171 at 11:00 a.m. EST.
• · The record date for determining stockholders entitled to vote is September 30, 2026.
• · A quorum requires a majority of all votes entitled to be cast.
• · To be elected, each director nominee must receive a majority of votes present in person or by proxy, assuming a quorum is present.
• · Withheld votes and broker non-votes will have the effect of a vote against each nominee.
• · The Board of Directors recommends a vote FOR each of the four nominees.
• · The proxy statement and materials were first mailed to stockholders on or about October 7, 2026.
• · The 2025 Annual Report on Form 10-K was previously mailed on or about April 15, 2026.

01-10-2026

Sysco Corporation filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders, to be held virtually on November 13, 2026. The filing highlights strong fiscal year 2026 results, exceeding earnings commitments and strengthening competitive position, while also detailing director elections, executive compensation, and the ratification of Ernst & Young LLP as independent auditor. The letter from leadership emphasizes momentum driven by improving USFS local volume trends and AI/technology transformation, but does not disclose specific financial figures or negative metrics.

• · Annual Meeting to be held virtually on November 13, 2026 at 7:00 a.m. Central Time.
• · Proposals include election of directors, advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor.
• · The filing includes CEO Pay Ratio and Pay Versus Performance disclosures.
• · The company reported strong fiscal year 2026 results and exceeded earnings commitments.
• · Improving USFS local volume trends were cited as a key driver of momentum.

01-10-2026

ResMed Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting, reporting strong FY2026 results with revenue growing 8% in constant currency, non-GAAP diluted EPS up 17%, and over $1.6 billion in free cash flow. The company returned over $1 billion to stockholders through dividends and share repurchases, a more than 70% increase from the prior year. However, the filing also notes the divestiture of the MatrixCare business and a leadership transition with CFO Brett Sandercock stepping down after two decades, while the Board size will be reduced from 11 to 10 directors following the retirement of Lead Director Ron Taylor.

• · Annual Meeting will be held virtually on November 18, 2026 (US Pacific) / November 19, 2026 (Australian Eastern Time).
• · Record date for voting is September 22, 2026 (US Eastern) / September 23, 2026 (Australian Eastern).
• · Noctrix Health acquisition expands into restless legs syndrome (RLS), with an estimated total addressable market of 400 million patients worldwide.
• · MatrixCare divestiture closed on September 1, 2026.
• · Board size to be reduced from 11 to 10 directors following Ron Taylor's retirement.
• · CFO transition: Brett Sandercock stepped down after over 20 years; Aaron Bloomer appointed as new CFO.

01-10-2026

Madison ETFs Trust filed a definitive proxy statement (DEF 14A) on October 1, 2026, calling a special shareholder meeting for November 24, 2026. Shareholders will vote on a new advisory agreement that reduces advisory fees but shifts certain operating expenses to the Funds, and on the election of four trustees. The net total expense ratio for each Fund is not expected to change under the new fee arrangement, and the Adviser will cover all transition and solicitation costs.

• · Record date for voting is September 25, 2026.
• · Proxy materials will be mailed to shareholders beginning on or about October 7, 2026.
• · The special meeting will be held on November 24, 2026 at 10:00 a.m. Central Time.
• · Shareholders can vote by mail, telephone, or internet.
• · The Adviser will pay all expenses related to the proxy solicitation and transition to the new fee arrangement.
• · The sub-adviser (Tidal Investments, LLC) will remain unchanged.
• · The new advisory agreement requires separate approval by shareholders of each Fund.
• · Approval of the new advisory agreement by one Fund is not contingent on approval by other Funds.

01-10-2026

Akari Therapeutics Plc filed a DEF 14A proxy statement on October 1, 2026, seeking shareholder approval to increase shares available under the 2023 Equity Incentive Plan by 144,000,000,000 ordinary shares (1,800,000 ADSs), from 19,806,000,000 to 163,806,000,000 ordinary shares. As of October 1, 2026, there were 16,272,945,001 ordinary shares subject to outstanding stock options with a weighted average exercise price of $0.00055 and a weighted average remaining term of 8.8 years, plus 1,200,000,000 unvested performance-based restricted stock units. The company had only 484,739,210 ordinary shares remaining available for future awards, indicating a need for additional equity incentives for approximately 21 eligible participants.

• · The Share Increase was approved by the Board on September 29, 2026, subject to shareholder approval at the Meeting.
• · No awards may be granted under the Amended Plan after June 5, 2033.
• · Options granted under the Amended Plan have a maximum term of ten years from date of grant.
• · Incentive stock options are limited to $100,000 in value becoming exercisable per participant per year.
• · The compensation committee may accelerate vesting of options and adjust awards for stock dividends, splits, and similar events.
• · In a corporate transaction, outstanding options may be assumed, accelerated, or cashed out at the committee's discretion.

01-10-2026

Modular Medical, Inc. filed a definitive proxy statement (DEF 14A) for its fiscal 2027 Annual Meeting of Shareholders to be held virtually on October 23, 2026. Key proposals include the election of six directors, approval of an amendment to the 2017 Equity Incentive Plan to increase authorized shares by 2,500,000, and ratification of Farber Hass Hurley LLP as independent auditor. The filing also discloses executive compensation data: the PEO's compensation actually paid was $17,055 in fiscal 2026 (versus $0 in fiscal 2025), while average compensation actually paid to non-PEO NEOs increased 8.0% to $542,365 from $502,206.

• · Annual Meeting will be held virtually on October 23, 2026 at 8:00 a.m. Pacific time.
• · Record date for voting is September 10, 2026.
• · Proposal 1: Election of six directors for one-year terms.
• · Proposal 2: Amendment to 2017 Equity Incentive Plan to increase shares by 2,500,000.
• · Proposal 3: Ratification of Farber Hass Hurley LLP as independent auditor for fiscal year ending March 31, 2027.
• · PEO compensation actually paid in fiscal 2026 was $17,055, compared to $0 in fiscal 2025.
• · Average compensation actually paid to non-PEO NEOs increased 8.0% to $542,365 in fiscal 2026 from $502,206 in fiscal 2025.

01-10-2026

Gold.com, Inc. filed a DEF 14A proxy statement with the SEC on October 1, 2026, for its virtual Annual Meeting of Stockholders to be held on November 12, 2026. The filing details voting procedures for stockholders of record as of September 17, 2026, including proposals to elect ten directors. The company is using the Internet as the primary means of distributing proxy materials.

• · The Annual Meeting will be held virtually on November 12, 2026 at 9:00 a.m. Pacific Time via the Meeting Website at https://www.meetnow.global/MS5RG6R.
• · Beneficial owners must pre-register with Computershare by November 4, 2026 to vote at the meeting.
• · Stockholders of record as of September 17, 2026 are entitled to vote.
• · The company's 2026 Annual Report and Form 10-K are available without charge by contacting the Corporate Secretary.